VINC

Vincerx Pharma, Inc. - Common Stock (VINC)

About Vincerx Pharma, Inc. - Common Stock (VINC)

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.

Details

Daily high
$0.06
Daily low
$0.05
Price at open
$0.06
52 Week High
$17.17
52 Week Low
$0.04
Market cap
287,900
Dividend yield
0.00%
Volume
6,210
Avg. volume
104,558
P/E ratio
-.01

Vincerx Pharma, Inc. - Common Stock News

Details

Daily high
$0.06
Daily low
$0.05
Price at open
$0.06
52 Week High
$17.17
52 Week Low
$0.04
Market cap
287,900
Dividend yield
0.00%
Volume
6,210
Avg. volume
104,558
P/E ratio
-.01